Peptides for Menopause: The New Gray-Market Trend

Women dealing with hot flashes, brain fog, fatigue, weight changes, joint pain and low libido are increasingly encountering an unexpected category of products online:

Experimental peptides.

Recent reporting has described women in their forties and fifties purchasing compounds such as BPC-157, CJC-1295, ipamorelin, GHK-Cu and investigational metabolic drugs through peptide suppliers, wellness communities and social media recommendations.

Some users describe major improvements.

One woman interviewed in September 2026 said she had experimented with around ten different peptides and attributed improvements in symptoms including fatigue, night sweats and brain fog to them. Another described turning to experimental retatrutide after insurance would not cover Wegovy. Others reported combining several compounds while exchanging information through private groups and coded social-media language.

These are personal experiences, not controlled clinical-trial results.

That distinction matters because most of the experimental peptides now appearing in menopause communities have not been adequately tested as treatments for menopause or perimenopause.

Some have limited human research for completely different purposes.

Others rely predominantly on animal or laboratory research.

Several have also been flagged by the US Food and Drug Administration because human safety information remains limited.

This has created an unusual new corner of women's health: people with very real symptoms are experimenting with substances that were never clinically established as menopause treatments.

There is currently no established experimental peptide treatment for menopause itself.

Menopause is associated with changes in ovarian hormone production, particularly declining estrogen and progesterone.

The experimental peptides appearing in online menopause communities generally act through very different biological systems.

CJC-1295 and ipamorelin affect the growth hormone axis.

BPC-157 is promoted largely around tissue repair, pain, gastrointestinal health and recovery.

GHK-Cu has been investigated mainly in skin, copper signalling and tissue biology.

Retatrutide targets metabolic pathways involved in appetite and body weight.

None of those mechanisms replaces estrogen or reverses the underlying menopausal transition.

That does not mean every symptom occurring during menopause must be treated with hormone therapy.

Weight, sleep, sexual function, mood, musculoskeletal symptoms and metabolic disease can involve many biological pathways.

But affecting one of those pathways does not automatically make a compound a treatment for menopause.

September 2026 reporting offered a detailed look inside this emerging community.

Women described experimenting with peptides for symptoms they associated with menopause or perimenopause, including:

• hot flashes
• fatigue
• cognitive difficulties
• weight gain
• low libido
• joint discomfort
• sleep problems

Some reported purchasing products directly online rather than through conventional pharmaceutical channels.

The reporting also described coded social-media terminology such as "peppers" for peptides.

The compounds appearing in these discussions span very different scientific and regulatory categories.

This is why the phrase "peptides for menopause" can be misleading.

It combines molecules with completely different mechanisms, evidence bases and regulatory histories.

The appeal is understandable from the patient's perspective.

Menopause can involve much more than hot flashes.

People may experience sleep disturbance, body-composition changes, genitourinary symptoms, sexual difficulties, mood changes and musculoskeletal discomfort.

At the same time, some women report feeling that their symptoms have been dismissed, misunderstood or inadequately treated.

That creates a receptive audience for a different message:

There is a molecule for every symptom.

Fatigue?

A growth-hormone peptide.

Weight gain?

A GLP-1 medicine or investigational metabolic drug.

Joint pain?

BPC-157.

Skin changes?

GHK-Cu.

Low sexual desire?

PT-141.

The marketing is appealing because it turns a complicated biological transition into a menu of apparently targeted interventions.

The scientific evidence is much less tidy.

One of the most common phrases in wellness marketing is that peptides can "rebalance hormones."

That phrase is often too vague to be medically useful.

Consider CJC-1295.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone.

A randomised human study published in 2006 found that a single administration of long-acting CJC-1295 increased mean growth hormone concentrations approximately twofold to tenfold for six days or longer and increased IGF-1 approximately one-and-a-half-fold to threefold for nine to eleven days.

Read the CJC-1295 human study on PubMed

DOI: 10.1210/jc.2005-1536

That is a real human pharmacological effect.

But the participants were healthy adults.

It was not a menopause trial.

Researchers were studying growth hormone and IGF-1.

They were not determining whether CJC-1295 reduced hot flashes, treated vaginal symptoms, restored ovarian estrogen production or improved menopause-related cognitive complaints.

An endocrine effect does not automatically establish a menopause benefit.

Ipamorelin is another growth hormone secretagogue frequently discussed alongside CJC-1295.

One early human pharmacology study examined eight healthy male volunteers at each of five infusion levels.

Researchers found that ipamorelin produced a temporary growth hormone response.

Read the ipamorelin human study on PubMed

DOI: 10.1023/A:1018955126402

Again, this provides meaningful pharmacological information.

But the participants were healthy men.

The study did not investigate:

• menopausal women
• hot flashes
• menopausal sleep disturbance
• long-term body-composition changes in midlife women
• menopause-related sexual symptoms
• long-term repeated use

The evidence therefore cannot establish ipamorelin as a menopause treatment.

The evidence gap is not merely theoretical.

FDA currently states that clinical data for CJC-1295 are limited and identifies concerns involving immunogenicity, peptide-related impurities and active pharmaceutical ingredient characterisation.

FDA also reports serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.

For ipamorelin acetate, FDA identifies concerns involving immunogenicity, aggregation, peptide-related impurities and the complexity created by unnatural amino acids.

FDA also notes serious adverse events, including death, in a study in which intravenous ipamorelin was investigated for gastrointestinal motility.

Those observations should not be converted into a claim that every route or use of ipamorelin causes the same outcomes.

They do, however, make broad statements such as "ipamorelin is proven safe" difficult to support.

Read FDA's current safety information on compounded peptide substances

The available evidence does not establish CJC-1295 or ipamorelin as safe and effective treatments for menopausal symptoms.

BPC-157 may be one of the most recognisable compounds in the current peptide boom.

A September 2026 preprint analysed electronic health records from a network containing approximately 15.2 million patients.

Researchers identified 1,039 patients with documented BPC-157 administration.

Newly documented users increased from four in the first quarter of 2020 to 134 in the first quarter of 2026, approximately a 33-fold increase.

Read the September 2026 BPC-157 preprint

That figure needs context.

The study is a preprint and has not undergone peer review.

It also measures documented use within a particular healthcare network, not the prevalence of BPC-157 use across the entire United States.

The study found that documented reasons for using BPC-157 commonly involved pain, gastrointestinal problems, injuries and post-surgical recovery.

It was not a menopause study.

The authors also explicitly stated that their observational data could not establish effectiveness because of factors including co-treatments, placebo effects, selection bias and reporting bias.

This is particularly important when the study is used in marketing.

A 33-fold increase in documented use tells us that interest is rising.

It does not prove that BPC-157 works.

FDA states that compounded drugs containing BPC-157 may present concerns involving:

• immunogenicity
• peptide-related impurities
• active pharmaceutical ingredient characterisation

The agency says that it has identified no or only limited safety-related information for proposed routes of administration and lacks sufficient information to determine whether BPC-157 would cause harm when administered to humans.

Read FDA's BPC-157 safety assessment

There is currently no established clinical-trial evidence demonstrating that BPC-157 treats hot flashes, menopausal cognitive symptoms, menopause-related fatigue or the hormonal transition responsible for menopause.

For more background, see BPC-157 Use Has Exploded 33-Fold Since 2020.

GHK-Cu is a copper-binding peptide that has attracted scientific interest because of its role in skin and tissue biology.

That has obvious appeal during menopause, when declining estrogen can be associated with changes in skin structure and collagen.

But one important distinction is frequently blurred:

Topical and injectable use are not the same exposure.

Evidence involving a cosmetic peptide applied to the skin should not automatically be used to establish the safety of injecting the molecule.

FDA specifically identifies potential immunogenicity concerns involving compounded injectable GHK-Cu, including possible aggregation and peptide-related impurities, and says human safety data for injectable use are limited.

Read FDA's current GHK-Cu safety information

Saying that GHK-Cu has been studied in skin biology is therefore not equivalent to saying injectable GHK-Cu is an established treatment for menopausal skin changes.

PT-141 is a particularly important example because the active compound, bremelanotide, is available as an FDA-approved medicine called Vyleesi.

That makes some online claims sound more convincing.

But the approved indication is specific.

Vyleesi is FDA-approved for acquired, generalised hypoactive sexual desire disorder in qualifying premenopausal women when the condition is not explained by another medical or psychiatric condition, relationship problems or the effects of another medicine or substance.

Its current prescribing information specifically states that Vyleesi is not indicated for postmenopausal women and is not approved simply to enhance sexual performance.

Read the current Vyleesi prescribing information on DailyMed

That population distinction matters.

An FDA-approved medicine for one female sexual-health indication does not automatically become an FDA-approved treatment for menopause-related sexual symptoms.

Weight change during midlife is one reason metabolic medicines are appearing in the same discussions as experimental peptides.

Semaglutide and tirzepatide have extensive randomised clinical-trial programmes supporting approved metabolic indications.

They should not be placed in the same evidence category as BPC-157 or CJC-1295.

But they are also not approved as treatments for menopause itself.

If a woman in perimenopause has obesity and meets the criteria for an approved weight-management treatment, the medicine is addressing the weight-management indication.

It is not reversing the menopause transition.

That distinction matters because changes in weight do not automatically address vasomotor symptoms, genitourinary symptoms or declining ovarian hormone production.

Retatrutide has now produced substantial Phase 3 obesity data.

Lilly reported in May 2026 that its TRIUMPH-1 Phase 3 trial met its primary and key secondary endpoints.

But retatrutide remains investigational.

It is not an FDA-approved medicine.

FDA currently states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition by FDA, and cannot be used in compounding under US federal law.

Read FDA's current information on unapproved GLP-1 drugs and retatrutide

Read Lilly's Phase 3 TRIUMPH-1 announcement

A product sold online as retatrutide should therefore not be treated as equivalent to receiving Lilly's investigational product within a regulated clinical programme.

See also They Bought BPC-157, PT-141 and Retatrutide. The Lab Found Something Else..

The gray market should not be confused with conventional prescribing or legitimate clinical research.

In this context, the term generally refers to products circulating outside the standard pathway of an FDA-approved finished medicine supplied through conventional regulated pharmaceutical distribution.

Online peptide sellers frequently use phrases such as:

• research use only
• not for human consumption
• laboratory reagent
• research peptide

At the same time, social-media communities may openly discuss using the same products on themselves.

That contradiction is important.

A research-use label does not establish:

• pharmaceutical manufacturing quality
• clinical effectiveness
• sterility
• dose accuracy
• human safety

FDA also warns that compounded drugs themselves are not FDA-approved and therefore are not reviewed before marketing for safety, effectiveness and quality in the same way as approved finished medicines.

Read FDA's information for consumers and healthcare professionals on compounded drugs

This distinction matters because peptide communities increasingly emphasise laboratory testing.

A seller may publish:

• an HPLC purity result
• a mass-spectrometry report
• an independent laboratory certificate
• a batch-specific COA

These can provide useful analytical information about a tested sample.

They cannot demonstrate that BPC-157 treats menopausal joint pain.

They cannot demonstrate that CJC-1295 improves menopausal sleep.

They cannot establish the long-term safety of injectable GHK-Cu.

Analytical chemistry asks:

What is present in this sample, and what did the analytical test measure?

Clinical research asks:

What happens when people use the treatment?

Those are different scientific questions.

For more detail, see Bali's Peptide Sellers Are Showing Lab Reports. Can You Trust Them?.

The September 2026 reporting also described mistakes among people experimenting with these compounds.

One woman said she accidentally used substantially more CJC-1295 than intended and subsequently developed pronounced swelling.

Another described an injection-related injury while using an injectable copper peptide.

These are individual accounts.

They do not establish the overall incidence or safety profile of either compound.

But they illustrate a separate issue:

Even when a vial contains the intended material, self-administering an injectable substance can create additional opportunities for harm.

These can include:

• measurement errors
• contamination
• product misidentification
• injection-related injuries
• unstudied combinations
• unexpected interactions

The uncertainty becomes greater when several experimental substances are used simultaneously.

Peptide communities commonly discuss "stacks", meaning combinations of several compounds.

Examples include:

CJC-1295 plus ipamorelin.

BPC-157 plus TB-500.

A metabolic medicine combined with one or more experimental recovery peptides.

The theory is often that different compounds work through different pathways and may therefore complement one another.

But combining two poorly studied interventions does not create better evidence.

If neither compound has been adequately studied for menopause individually, the combination is even less certain.

Interactions may not have been systematically evaluated.

Adverse effects become more difficult to attribute.

And if symptoms improve, it can become impossible to determine which intervention was responsible.

A 2026 rat study of BPC-157 and TB-500 in Achilles tendon healing illustrates the point. Researchers studied the compounds individually and together; the combination did not demonstrate additional benefit over the individual compounds across the study's main comparisons.

This was an animal experiment and cannot establish human effectiveness.

See The Wolverine Stack Is Going Mainstream.

The established menopause-treatment evidence base looks very different from the experimental peptide market.

The Menopause Society's hormone-therapy position statement describes hormone therapy as the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and notes that it can prevent bone loss and fracture.

The same statement emphasises that risks vary according to factors including:

• treatment type
• dose
• duration
• route
• timing of initiation
• whether a progestogen is used

It recommends individualised benefit-risk assessment and periodic reevaluation.

Read the 2022 Menopause Society position statement on PubMed

DOI: 10.1097/GME.0000000000002028

This is not evidence that hormone therapy is risk-free.

It is evidence that its benefits, limitations and risks have been studied extensively enough to support individual clinical decision-making.

This point needs precision.

On February 12, 2026, FDA announced approved labelling changes for an initial group of six menopausal hormone-therapy products.

Those six products were:

• Prometrium
• Divigel
• Cenestin
• Enjuvia
• Estring
• Bijuva

See FDA's list of the six products with updated prescribing information

The changes removed language concerning cardiovascular disease, breast cancer and probable dementia from the boxed warnings of those six products.

The action followed FDA's November 2025 request for wider hormone-therapy labelling changes.

But it did not mean hormone therapy had become risk-free.

For systemic products, FDA retained cardiovascular-disease and breast-cancer information elsewhere in the prescribing information.

The agency also retained the boxed warning regarding endometrial cancer for systemic estrogen-alone products.

FDA's action was intended to revise how risks and benefits are communicated, not to declare that every patient has the same risk profile.

Read FDA's February 12, 2026 announcement

Read FDA's detailed explanation of the requested labelling changes

This distinction matters because removing particular statements from a boxed warning is not the same thing as removing all safety considerations.

Treatment still requires individual assessment.

Women who cannot or do not want to use hormone therapy are not limited to experimental peptides.

Two important FDA-approved nonhormonal examples are fezolinetant and elinzanetant.

Fezolinetant

Fezolinetant, marketed as Veozah, was FDA-approved in 2023 for moderate to severe vasomotor symptoms due to menopause.

FDA says the original approval was based on three clinical trials involving 2,859 participants; 2,852 received Veozah 45 mg, fezolinetant 30 mg or placebo.

Read FDA's Veozah Drug Trials Snapshot

Postmarketing surveillance subsequently identified an important safety issue.

In December 2024, FDA added a boxed warning concerning rare but serious liver injury and strengthened liver-monitoring requirements.

Read FDA's Veozah liver-safety communication

That sequence illustrates what an established regulatory system can look like:

clinical trials before approval

followed by continued safety monitoring

followed by label changes when new safety information emerges.

Elinzanetant

Elinzanetant, marketed as Lynkuet, was FDA-approved on October 24, 2025 for moderate to severe vasomotor symptoms due to menopause.

FDA approved Lynkuet based on evidence from three clinical studies:

OASIS-1

OASIS-2

and OASIS-3.

The three studies involved 1,423 participants.

Of those participants, 1,420 received either Lynkuet 120 mg or placebo during the studies.

The FDA safety population therefore comprised 1,420 treated participants.

Read FDA's Lynkuet Drug Trials Snapshot

The distinction between 1,423 study participants and 1,420 treated participants should be preserved rather than treating the figures as contradictory.

A simplified comparison looks like this:

This table should not be read as a recommendation for or against any individual treatment.

The appropriate choice depends on the condition being treated, medical history, contraindications, other medicines and individual risk factors.

There is a reason experimental peptide communities can grow even before convincing clinical trials exist.

Menopause symptoms fluctuate.

They can improve and worsen over time.

People may also change several things simultaneously:

• diet
• exercise
• hormone therapy
• supplements
• sleep habits
• other medicines
• body weight

If someone starts a peptide during the same period and later feels better, it is understandable that they may attribute the change to the peptide.

The experience itself may be genuine.

The cause remains uncertain.

Without an appropriate comparison group, researchers cannot easily separate:

• treatment effects
• natural symptom fluctuation
• placebo effects
• weight loss
• other medicines
• lifestyle changes
• regression toward the mean

Testimonials can generate research questions.

They cannot establish treatment effectiveness.

The menopause peptide trend is closely connected to social media.

Recent reporting describes communities using code words such as:

• peppers
• pepper farmers
• semolina
• ratatouille

For some users, the language is intended to reduce the risk of content moderation.

But coded terminology can also hide important scientific distinctions.

Someone hearing "ratatouille" may not realise the discussion concerns retatrutide, an investigational drug.

Someone hearing "peppers" may not realise that one discussion concerns an approved metabolic medicine while another concerns an experimental compound with minimal human evidence.

See Why Are People Creating Secret Code Words for Peptides Online?.

Scientific evidence depends on precise terminology.

Gray-market culture can move in the opposite direction.

"Peptides are natural, so they are safer than hormone therapy"

The word peptide describes a molecular category.

It is not a safety rating.

Some peptide medicines have substantial clinical safety evidence.

Others have very little human exposure data.

Synthetic modifications can also substantially alter how long a peptide remains active and how it behaves biologically.

"These peptides stimulate your own hormones instead of replacing them"

Some compounds influence endocrine pathways.

That does not mean they restore normal menopausal physiology.

CJC-1295 increasing growth hormone and IGF-1, for example, does not replace declining ovarian estrogen.

"If a doctor prescribes a peptide, it must be proven"

Not necessarily.

Approved prescribing, off-label use, compounding and use of experimental substances involve different evidence and regulatory questions.

The exact molecule, product and indication need to be evaluated separately.

"If women online say their hot flashes stopped, the peptide must work"

A testimonial can identify a possible signal.

It cannot establish causation.

Controlled studies are needed to determine whether the treatment itself produced the improvement.

"PT-141 is FDA-approved for low libido, so it is approved for menopausal women"

No.

The current Vyleesi label applies to qualifying premenopausal women with acquired, generalised HSDD.

The label explicitly says the medicine is not indicated for postmenopausal women.

"Research use only means the product is basically a medicine waiting for approval"

No.

Research labelling does not establish pharmaceutical quality, clinical effectiveness, regulatory approval or suitability for human use.

There is no reliable national estimate of how many menopausal or perimenopausal women are using gray-market peptides.

Journalistic reporting demonstrates that the behaviour exists.

Online communities show significant interest.

Broader scientific and regulatory literature confirms that an unapproved peptide market exists.

None of those sources can tell us accurately what proportion of menopausal women are currently using these compounds.

Likewise, there is no large randomised clinical trial demonstrating that BPC-157, CJC-1295, ipamorelin or injectable GHK-Cu improves the core symptoms of menopause.

That absence should be interpreted carefully.

For several compounds, the appropriate trials have simply not been performed.

Lack of evidence is not the same as a large trial proving that a treatment does not work.

It means the answer remains unknown.

If CJC-1295 were proposed as a treatment for menopausal sleep disturbance, researchers would need to study the relevant population experiencing that problem.

The trial would require:

• clearly defined participants
• predefined outcomes
• an appropriate comparison group
• adequate duration
• systematic adverse-event monitoring

If BPC-157 were proposed for musculoskeletal symptoms in menopausal women, researchers would need to define the condition being treated and measure clinically meaningful outcomes.

If an experimental compound were proposed for hot flashes, trials would need to measure the frequency and severity of vasomotor symptoms against an appropriate comparator.

If multiple peptides were proposed as a stack, the combination itself would need to be evaluated.

That is how biological plausibility becomes clinical evidence.

Without that process, consumers risk performing the experiment themselves.

Are Peptides Becoming Popular for Menopause?

Recent reporting and online activity indicate meaningful interest among menopausal and perimenopausal women.

There is currently no reliable population-level estimate showing how common gray-market peptide use is within this group.

Which Peptides Are Women Using?

Recent discussions include compounds such as BPC-157, CJC-1295, ipamorelin and GHK-Cu, as well as metabolic medicines such as semaglutide and tirzepatide and investigational retatrutide.

Their mechanisms, evidence bases and regulatory status differ substantially.

Is BPC-157 Proven to Help Menopause Symptoms?

No controlled human evidence has established BPC-157 as a treatment for hot flashes, menopausal cognitive symptoms, menopausal fatigue or the underlying hormonal transition.

Do CJC-1295 and Ipamorelin Help Women Over Forty?

Both compounds can influence the growth hormone axis.

That does not establish that either compound, or their combination, treats menopause symptoms.

The early ipamorelin pharmacology study discussed above was performed in healthy male volunteers.

Can Experimental Peptides Replace Menopausal Hormone Therapy?

Compounds such as BPC-157, CJC-1295 and ipamorelin do not replace estrogen and should not be described as equivalent to menopausal hormone therapy.

They act through different biological pathways.

Is PT-141 Approved for Menopause-Related Low Libido?

Bremelanotide is FDA-approved for acquired, generalised HSDD in certain premenopausal women.

The approved indication does not include postmenopausal women.

Are Semaglutide and Tirzepatide Menopause Treatments?

No.

They are established medicines used for specified metabolic indications.

A woman experiencing menopause may separately qualify for one of those indications, but that does not make the medicine a treatment for menopause itself.

Does the 2026 FDA Hormone-Therapy Label Change Mean HRT Is Now Risk-Free?

No.

The February 12, 2026 approval applied initially to six named products: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva.

Specific cardiovascular-disease, breast-cancer and probable-dementia language was removed from their boxed warnings.

That did not remove every safety consideration from the prescribing information and did not make hormone therapy risk-free.

The appropriate benefit-risk assessment still depends on the individual patient and treatment.

Why Can Gray-Market Peptides Be Risky?

Potential concerns include:

• limited human safety evidence
• incorrect quantities
• misidentified products
• contamination
• peptide-related impurities
• uncertain sterility
• self-administration errors
• interactions between multiple experimental substances

The magnitude of those risks varies by product and situation and cannot be inferred from the word peptide alone.

The emergence of experimental peptides in menopause communities says something important about women's health.

Women experiencing disruptive symptoms are actively looking for answers.

Some feel conventional healthcare has not adequately addressed their concerns.

Peptide communities offer an appealing model:

Identify the symptom, then find a molecule that appears to target it.

But the science has not caught up with that model.

CJC-1295 can alter growth hormone signalling.

Ipamorelin can stimulate growth hormone release.

BPC-157 has intriguing preclinical biology and rapidly increasing documented use.

GHK-Cu has legitimate scientific interest.

Approved metabolic medicines can produce major changes in body weight.

None of those facts automatically means these compounds treat menopause.

For several of the most popular experimental peptides, researchers have not established whether they improve menopausal symptoms, what long-term risks they may present in midlife women or what happens when several are combined.

Menopause medicine already includes treatments supported by controlled human evidence, including hormone therapies and approved nonhormonal treatments.

Those established treatments are not risk-free either.

The difference is that their benefits, limitations, populations and important risks have been studied much more systematically.

Experimental peptides may eventually lead to useful treatments.

But personal testimonials, laboratory purity reports and biological theories should not be mistaken for evidence that the necessary clinical research has already been completed.

1. FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks

Current FDA safety information addressing BPC-157, CJC-1295, injectable GHK-Cu, ipamorelin and other experimental peptide substances.

1. Teichman SL et al. CJC-1295 in Healthy Adults

Human randomised pharmacology research demonstrating prolonged GH and IGF-1 stimulation after CJC-1295.

DOI: 10.1210/jc.2005-1536

1. Gobburu JVS et al. Ipamorelin Pharmacokinetics and Pharmacodynamics in Human Volunteers

Human pharmacology study conducted in healthy male volunteers.

DOI: 10.1023/A:1018955126402

1. Venkatakrishnan AJ et al. Rising Use of Unapproved BPC-157

September 2026 preprint analysing approximately 15.2 million electronic health records and identifying 1,039 patients with documented BPC-157 administration. This source has not been peer reviewed.

1. DailyMed: Current Vyleesi Prescribing Information

Official prescribing information for bremelanotide, including its specific premenopausal HSDD indication and limitation regarding postmenopausal women.

1. FDA: Concerns With Unapproved GLP-1 Drugs

Current FDA information confirming that retatrutide is not FDA-approved and cannot be used in compounding under US federal law.

1. The Menopause Society: 2022 Hormone Therapy Position Statement

Expert consensus statement addressing the benefits, risks and individualisation of menopausal hormone therapy.

DOI: 10.1097/GME.0000000000002028

1. FDA: February 2026 Menopausal Hormone Therapy Labelling Changes

FDA announcement covering the first six hormone-therapy products with approved labelling changes.

1. FDA: Menopausal Hormone Therapies With Updated Prescribing Information

FDA's list identifying Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva.

1. FDA: Detailed Hormone-Therapy Benefit-Risk Labelling Changes

Explains which boxed-warning statements FDA requested removed, which safety information remains elsewhere in labelling and the continuing need for individualised assessment.

1. FDA Drug Trials Snapshot: Veozah

FDA summary of the three trials involving 2,859 participants that supported the original approval of fezolinetant.

1. FDA: Veozah Serious Liver Injury and Boxed Warning

FDA postmarketing safety communication concerning rare but serious liver injury and required liver monitoring.

1. FDA Drug Trials Snapshot: Lynkuet

FDA confirms that OASIS-1, OASIS-2 and OASIS-3 involved 1,423 participants, of whom 1,420 received Lynkuet or placebo.

1. Lilly: TRIUMPH-1 Phase 3 Retatrutide Results

Sponsor's Phase 3 results announcement. Retatrutide remains investigational.

New York Post: Women Using Experimental Peptides During Menopause, September 22, 2026

This reporting is used for the individual experiences and descriptions of online peptide communities discussed at the beginning of the article. Those accounts should not be interpreted as clinical evidence.

Medical Disclaimer

This article is provided for educational and research purposes only and is not intended as medical advice, diagnosis or treatment guidance. Informal or online terminology does not indicate that a substance is approved, safe, effective or appropriate for human use. Experimental peptides and investigational drugs may have limited human evidence and may not have established safety or effectiveness. Personal medical decisions should be discussed with a qualified healthcare professional, and information about medicines should be verified through recognised regulatory authorities, clinical trial registries and other reliable medical sources.